A Phase 4 clinical trial for JATENZO as T therapy for female-to-male transgender individuals
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Clarus Therapeutics
- 08 Apr 2022 New trial record
- 30 Mar 2022 Phase 4 clinical trial for JATENZO as T therapy for female-to-male transgender individuals (labeling expansion; Investigator-Initiated Study) expected to be initiated in the second half of 2022